Hepatitis C: All adults in U.S. — under 80 — should be tested

By Beth Duff-Brown: For More Info, Go Here…

The hepatitis C virus now kills more Americans than all other reportable infectious diseases combined — including HIV. Acute cases of HCV have increased 3.5-fold over the last decade, particularly among young, white, injection drug users.

Women aged 15 to 44 have also been hit hard by the virus that is spread through contaminated blood, and the prevalence of HCV infection among women giving birth has nearly doubled.

Those staggering details were revealed earlier this week when the U.S. Preventive Services Task Force issued a draft recommendation that calls on clinicians to screen all adults 18 to 79 years old for the virus, even those with no symptoms or known liver disease.

The opioid epidemic has fueled what is now the most common chronic bloodborne pathogen, said Stanford Health Policy’s Douglas Owens, MD, chair of the independent, voluntary panel of national experts in prevention and evidence-based medicine.

The Task Force, which makes recommendations followed by primary care clinicians nationwide, has until now recommended hepatitis C testing for people who are at high risk, as well as baby boomers born between 1945 and 1965.

“Unfortunately, HCV now affects a broader age range than previously with three times as many new infections per year,” said Owens.

I wondered how the dramatic increase in HCV infection was impacting clinical practices, so I turned to Stanford Medicine hepatologist Amanda Cheung, MD.

Cheung said that because patients with chronic HCV typically do not have symptoms until many decades after exposure, she hasn’t yet seen the downstream impact of this new wave of infection. But once those patients discover the infection, she said, “it’s already started to wreak havoc on their bodies and causes development of cirrhosis, liver failure, liver cancer, or death.”

Cheung said the baby boomer population is a great example.

“Until guidelines started to advise screening for patients within this birth cohort, these patients were arriving to hepatology offices worldwide with end-stage liver disease and the patients had no clue that they harbored such a high-risk infection,” she told me.

Until just a few years ago, there was no universally effective treatment for hepatitis C that was well tolerated by patients, Cheung said. But the landscape has changed dramatically and clinicians are now able to successfully cure at least 95% of patients with the chronic condition with oral medications that have little or no side effects.

“With such an effective means for cure, it only makes sense to universally screen patients,” Cheung said.

Leave a Reply